SEC Form 4 · accession 0001103780-16-000077
Lexaria Bioscience Corp. · LXRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bunka
Officer — CEO · Director · 10% Owner
Period of report
Jan 20, 2010
Accepted (ET)
Jan 7, 2016 · 8:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348362
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jan 6, 2016 | P | 3,990 | $0.151 | A | 4,961,844 | I | Private holding company |
| Common Shares | Jan 7, 2016 | P | 5,000 | $0.151 | A | 4,966,844 | I | Private holding company |
| Common Shares | holding | — | — | — | 4,957,854 | I | Private holding company | |
| Common Shares | holding | — | — | — | 6,908,814 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $0.10 | holding | — | — | — | Dec 23, 2014 | Dec 23, 2019 | Common Shares | 550,000 | 550,000 | D |
| Stock Options | $0.32 | holding | — | — | — | Jul 11, 2011 | Jul 11, 2016 | Common Shares | 220,000 | 770,000 | D |
| Stock Options | $0.09 | holding | — | — | — | Jun 18, 2013 | Jun 18, 2018 | Common Shares | 247,500 | 1,017,500 | D |
| Warrants | $0.23 | holding | — | — | — | May 15, 2015 | May 15, 2017 | Common Shares | 187,000 | 187,000 | I |